

Prof. ONUR KESKİN

Personal Information

Email: onurkeskin@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/onurkeskin>

International Researcher IDs

ORCID: 0000-0002-9790-8204

Yoksis Researcher ID: 184420

Education Information

Post Doctorate of Medicine, Ankara University, Faculty Of Medicine, Department Of Internal Medicine, Turkey 2011 - 2014

Expertise In Medicine, Ankara University, Faculty Of Medicine, Department Of Internal Medicine, Turkey 2005 - 2010

Postgraduate, Hacettepe University, Tıp Fakültesi (İngilizce), Turkey 1998 - 2005

Foreign Languages

English, C1 Advanced

Research Areas

Health Sciences

Academic Titles / Tasks

Associate Professor, Hacettepe University, Tıp Fakültesi (Türkçe), Dahili Tıp Bilimleri Bölümü, 2017 - Continues

Expert, Ankara University, Faculty Of Medicine, Department Of Internal Medicine, 2016 - 2017

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The Course of COVID-19 Infection in Patients With Chronic Hepatitis Delta**
PARLAR Y. E., Gulnar M. O., Kirmizigul B., Gencdal G., Zeybel M., KESKİN O., Yurdaydin C.
JOURNAL OF VIRAL HEPATITIS, vol.32, no.1, 2025 (SCI-Expanded)
- II. **Non-invasive fibrosis markers are useful in predicting the presence of varices in compensated cirrhosis and variceal bleeding in decompensated cirrhosis**
ORAL H., ÖZTÜRK B., KAV T., KESKİN O.
INTERNAL AND EMERGENCY MEDICINE, 2024 (SCI-Expanded)
- III. **Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history**
Gulnar M. O., Kamal H., Palom A., Arici S., Esteban R., TUNÇ E., KESKİN O., İDİLMAN R., Buti M., Aleman S., et al.
JOURNAL OF HEPATOLOGY, 2024 (SCI-Expanded)
- IV. **The respiratory assessment of cirrhotic patients: six-minute walk test is an independent predictor of mortality in cirrhosis**

GÜRBÜZ B., Idikut A., Karakulak U., DAMADOĞLU E., Kaya B., KAV T., PARLAK E., KESKİN O.

JOURNAL OF HEPATOLOGY, 2024 (SCI-Expanded)

- V. **Proceedings of the 28th Annual Congress of the International Liver Transplantation Society**
Shaji Mathew J., Shingina A., Khan M. Q., Wilson E., Syn N., Rammohan A., Alconchel F., Hakeem A. R., Shankar S., Patel D., et al.
Liver Transplantation, vol.30, no.5, pp.544-554, 2024 (SCI-Expanded)
- VI. **Risk of Bleeding After Percutaneous Endoscopic Gastrostomy in Patients Using Antithrombotic Drugs**
PARLAR Y. E., Mustafayev F., Vahabov C., ŞAHİN T., İsrailov S., KESKİN O., BALABAN H. Y., KAV T., PARLAK E., ŞİMŞEK H., et al.
Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, vol.33, no.5, pp.540-542, 2023 (SCI-Expanded)
- VII. **Proceedings of the 27th Annual Congress of the International Liver Transplantation Society**
Campos-Varela I., Rammohan A., Chadha R., Alconchel F., Hakeem A. R., Mathew J. S., Goldaracena N., Syn N., Shankar S., Patel D., et al.
Transplantation, vol.107, no.6, pp.1226-1231, 2023 (SCI-Expanded)
- VIII. **The DETAIL questionnaire is a useful and effective tool to assess spondyloarthritis in patients with inflammatory bowel disease**
KESKİN O., Farisogullari B., YARDIMCI G. K., GÜRBÜZ B., Kole M., PARLAK E., KARADAĞ Ö., KAV T., KALYONCU U.
Frontiers in Medicine, vol.10, 2023 (SCI-Expanded)
- IX. **The impact of COVID-19 disease on the natural course of cirrhosis: Before and after starting vaccination**
KESKİN O., ORAL H., Sahin T., KAV T., PARLAK E.
Frontiers in Medicine, vol.9, 2023 (SCI-Expanded)
- X. **Emerging drugs for hepatitis D**
KESKİN O., Yurdaydin C.
Expert Opinion on Emerging Drugs, vol.28, no.2, pp.55-66, 2023 (SCI-Expanded)
- XI. **Clinical and Endoscopic Consequences of Delay in Stent Exchange Procedures With ERCP During the Covid-19 Pandemic**
Keskin O., Kav T., Vahabov C., Usta B., Sivri B., Parlak E.
Surgical laparoscopy, endoscopy & percutaneous techniques, vol.32, no.6, pp.714-719, 2022 (SCI-Expanded)
- XII. **Outcomes of Surgical Strategies for Living Donor Liver Transplantation in Patients With Portal Vein Thrombosis: A Cohort Study**
KIRIMKER E. O., Kabacam G., KESKİN O., Goktug U. U., Atli M., KOLOĞLU M., Karayalcin K., Karademir S., Balci D.
Transplantation Proceedings, vol.54, no.8, pp.2217-2223, 2022 (SCI-Expanded)
- XIII. **The role of preoperative psychosocial counselling on the improvement of the recipient compliance and speed of recovery after liver transplantation – A systematic review of the literature and expert panel recommendations**
Weiss E., Kabacam G., Gorvin L., Spiro M., Raptis D. A., KESKİN O., Orloff S., Belghiti J.
Clinical Transplantation, vol.36, no.10, 2022 (SCI-Expanded)
- XIV. **Proceedings of the 26th Annual Virtual Congress of the International Liver Transplantation Society**
Kalisvaart M., Chadha R., De Martin E., Alconchel F., Goldaracena N., KESKİN O., Liu J., Nasralla D., Mazzola A., Rammohan A., et al.
TRANSPLANTATION, vol.106, no.9, pp.1738-1744, 2022 (SCI-Expanded)
- XV. **Quality of care for hepatitis B patients should include delta hepatitis screening**
KESKİN O.
INTERNAL MEDICINE JOURNAL, vol.52, no.8, pp.1457, 2022 (SCI-Expanded)
- XVI. **The course of COVID-19 infection in patients with chronic hepatitis B and Delta**
PARLAR Y. E., KESKİN O., KIRMIZIGÜL B., Gencdal G., Zeybel M., Gumussoy M., İDİLMAN R., Yurdaydin C.
JOURNAL OF HEPATOLOGY, vol.77, 2022 (SCI-Expanded)
- XVII. **Is the effect of coffee consumption on the development of fibrosis really different in treated and untreated hepatitis B patients?**
KESKİN O.

CLINICAL NUTRITION, vol.41, no.6, pp.1445, 2022 (SCI-Expanded)

- XVIII. **Hereditary angioedema and pancreatitis: two diseases that should remind each other**
Ismayilov R., Ismayilova U., KESKİN O.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.34, no.2, pp.240-241, 2022 (SCI-Expanded)
- XIX. **A NEW SCORING SYSTEM COMPOSED OF MMP-1, AST/ALT RATIO AND TOTAL METABOLIC SYNDROME SCORE CAN DETECT AT-RISK NASH PATIENTS WITH FIBROSIS STAGE \geq 2 MORE ACCURATELY THAN FIB-4 SCORE, NAFLD FIBROSIS SCORE, BARD SCORE, APRI SCORE AND MR ELASTOGRAPHY**
KÖYLÜ B., SÖKMENSÜER C., KESKİN O.
HEPATOLOGY, vol.74, 2021 (SCI-Expanded)
- XX. **Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us**
KESKİN O., Yurdaydin C.
HEPATOLOGY, vol.74, no.2, pp.1127, 2021 (SCI-Expanded)
- XXI. **Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study**
hesimov i., KIRIMKER E. O., DUMAN B., KESKİN O., ÇETİNKAYA Ö. A., HAYME S., ÜSTÜNER E., İDİLMAN R., Yurdaydin C., dökmeci a., et al.
TRANSPLANTATION PROCEEDINGS, vol.50, no.10, pp.3076-3081, 2018 (SCI-Expanded)
- XXII. **Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy**
Lutterkort G. L., Wranke A., Hengst J., Yurdaydin C., Stift J., Bremer B., Hardtke S., KESKİN O., İDİLMAN R., Manns M. P., et al.
JOURNAL OF VIRAL HEPATITIS, vol.25, no.11, pp.1384-1394, 2018 (SCI-Expanded)
- XXIII. **Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population**
Papatheodoridis G. V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Goulis J., Calleja J. L., Chi H., Manolakopoulos S., et al.
JOURNAL OF HEPATOLOGY, vol.68, no.6, pp.1129-1136, 2018 (SCI-Expanded)
- XXIV. **Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease**
Yurdaydin C., KESKİN O., KALKAN Ç., KARAKAYA M. F., Caliskan A., Kabaçam G., Onder F. O., Karatayli S., Karatayli E., Deda X., et al.
JOURNAL OF INFECTIOUS DISEASES, vol.217, no.8, pp.1184-1192, 2018 (SCI-Expanded)
- XXV. **Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study**
Yurdaydin C., KESKİN O., KALKAN Ç., KARAKAYA M. F., Caliskan A., KARATAYLI E., Karatayli S., BOZDAYI A. M., Koh C., Heller T., et al.
HEPATOLOGY, vol.67, no.4, pp.1224-1236, 2018 (SCI-Expanded)
- XXVI. **The Risk of Hepatocellular Carcinoma Decreases After the First 5 Years of Entecavir or Tenofovir in Caucasians With Chronic Hepatitis B**
Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., Luis Calleja J., Sypsa V., Goulis J., Manolakopoulos S., et al.
HEPATOLOGY, vol.66, no.5, pp.1444-1453, 2017 (SCI-Expanded)
- XXVII. **The association between gastroesophageal flap valve function and gastroesophageal reflux symptoms**
KESKİN O., KALKAN Ç., Yaman A., TÜZÜN A. E., SOYKAN A. İ.
ACTA GASTRO-ENTEROLOGICA BELGICA, vol.80, no.4, pp.471-475, 2017 (SCI-Expanded)
- XXVIII. **Non-invasive fibrosis score for hepatitis delta**
Lutterkort G. L., Wranke A., Yurdaydin C., Budde E., Westphal M., Lichtinghagen R., Stift J., Bremer B., Hardtke S., KESKİN O., et al.
LIVER INTERNATIONAL, vol.37, no.2, pp.196-204, 2017 (SCI-Expanded)

- XXIX. **Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up**
KARAKAYA M. F., özer s., Kalkan C., Tuzun E. A., Caliskan A., Keskin O., Kabacam G., KARATAYLI E., Karatayli E., Bozdayi A. M., et al.
ANTIVIRAL THERAPY, vol.22, no.7, pp.559-570, 2017 (SCI-Expanded)
- XXX. **The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence**
İDİLMAN R., AKYILDIZ M., KESKİN O., güngör g., yılmaz t. u., KALKAN Ç., DAYANGAÇ M., ÇINAR K., BALCI D., HAZİNEDAROĞLU S. M., et al.
CLINICAL TRANSPLANTATION, vol.30, no.10, pp.1216-1221, 2016 (SCI-Expanded)
- XXXI. **PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy**
Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., Luis Calleja J., Chi H., Manolakopoulos S., Mangia G., et al.
JOURNAL OF HEPATOLOGY, vol.64, no.4, pp.800-806, 2016 (SCI-Expanded)
- XXXII. **A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease**
İDİLMAN İ. S., Keskin O., CELİK A., Savas B., Elhan A. H., Idilman R., KARÇAALTINCABA M.
ACTA RADIOLOGICA, vol.57, no.3, pp.271-278, 2016 (SCI-Expanded)
- XXXIII. **Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome**
KESKİN O., Wedemeyer H., TÜZÜN A. E., Zachou K., Deda X., Dalekos G. N., Heidrich B., Pehlivan S., Zeuzem S., YALÇIN K., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.13, no.13, pp.2342-2351, 2015 (SCI-Expanded)
- XXXIV. **Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial**
Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Williams V. H., Winters M. A., Subramanya G., Cooper S. L., Pinto P., et al.
Lancet Infectious Diseases, vol.15, pp.1167-1174, 2015 (SCI-Expanded)
- XXXV. **How to evaluate gastroesophageal sphincter incompetence**
KESKİN O., KESKİN Ç.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.26, no.5, pp.439, 2015 (SCI-Expanded)
- XXXVI. **Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy**
SOYDAL Ç., KESKİN O., KÜÇÜK Ö., ÖZKAN E., BİLGİÇ M. S., İDİLMAN R., KIR K. M.
ANNALS OF NUCLEAR MEDICINE, vol.29, no.5, pp.426-430, 2015 (SCI-Expanded)
- XXXVII. **Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting**
İDİLMAN R., GÜNŞAR F., KORUK M., KESKİN O., MERAL C. E., GÜLŞEN M. T., ELHAN A. H., AKARCA U. S., Yurdaydin C.
JOURNAL OF VIRAL HEPATITIS, vol.22, no.5, pp.504-510, 2015 (SCI-Expanded)
- XXXVIII. **Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir**
Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Buti M., Goulis J., Arends P., Sypsa V., Manolakopoulos S., Mangia G., Gatselis N., et al.
JOURNAL OF HEPATOLOGY, vol.62, no.2, pp.363-370, 2015 (SCI-Expanded)
- XXXIX. **Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis**
KESKİN O., İDİLMAN R.
European Journal Of Gastroenterology & Hepatology, vol.27, pp.1228-1229, 2015 (SCI-Expanded)
- XL. **Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta**
KABAÇAM G., WEDEMEYER H., SAVAŞ B., KESKİN O., Dalekos G., TABAK Ö. F., İDİLMAN R., ERHARDT A., YALÇIN K.,

BOZDAYI A. M., et al.

LIVER INTERNATIONAL, vol.34, no.8, pp.1207-1215, 2014 (SCI-Expanded)

- XLII. **Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5' UTR regions in genotyping efficiency**
Alagoz G. K., Karatayli S. C., KARATAYLI E., ÇELİK E., KESKİN O., DİNÇ B., ÇINAR K., İDİLMAN R., Yurdaydin C., BOZDAYI A. M.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.4, pp.405-410, 2014 (SCI-Expanded)
- XLIII. **Autoimmune disease, tumor necrosis factor inhibitors and acute leukemia: possible associations in two patients?**
ÖZEN M., KESKİN O., TOPÇUOĞLU P., ÖZTÜRK B., ÖZGÜL S., İLGEN U., KÜÇÜKŞAHİN O., TURGAY T. M., TÖRÜNER M., GÜRMAN G.
LEUKEMIA & LYMPHOMA, vol.55, no.7, pp.1697-1698, 2014 (SCI-Expanded)
- XLIV. **Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy**
GÜRAKAR M., MALİK M., KESKİN O., İDİLMAN R.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.3, pp.304-308, 2014 (SCI-Expanded)
- XLV. **Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease**
Idilman I. S., KESKİN O., ELHAN A. H., IDILMAN R., Karcaaltincaba M.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.5, pp.617-624, 2014 (SCI-Expanded)
- XLVI. **Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta.**
Karatayli S. C., ÜLGER Z., Ergul A., KESKİN O., KARATAYLI E., ALBAYRAK R., ÖZKAN M. M., İDİLMAN R., YALÇIN K., BOZKAYA H., et al.
Journal of viral hepatitis, vol.21, no.4, pp.297-304, 2014 (SCI-Expanded)
- XLVII. **Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B**
KESKİN O., Ormeci A. C., BARAN B., KABAÇAM G., TÜZÜN A. E., KARATAYLI E., AKYÜZ F., Karatayli S., BOZDAYI A. M., ÖNEL D., et al.
ANTIVIRAL THERAPY, vol.19, no.6, pp.543-550, 2014 (SCI-Expanded)
- XLVIII. **Effect of endogenous hypergastrinemia on gallbladder volume and ejection fraction in patients with autoimmune gastritis**
YAKUT M., KESKİN O., SOYKAN A. İ.
Hepatobiliary & Pancreatic Diseases International, vol.11, pp.527-531, 2012 (SCI-Expanded)
- XLIX. **Clinical Profiles, Endoscopic and Laboratory Features and Associated Factors in Patients with Autoimmune Gastritis**
SOYKAN A. İ., YAKUT M., KESKİN O., BEKTAŞ M.
DIGESTION, vol.86, no.1, pp.20-26, 2012 (SCI-Expanded)
- L. **No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus**
Aksoy R., DUMAN M. T., KESKİN O., Düzgün N.
MOLECULAR BIOLOGY REPORTS, vol.38, no.8, pp.5393-5396, 2011 (SCI-Expanded)
- L. **Cytotoxic T lymphocyte antigen 4 CTLA 4 polymorphism in patients with Behçet s disease**
DÜZGÜN N., DUMAN M. T., KESKİN O., YONCA M., TUTKAK H.
Clinical and Experimental Rheumatology, vol.28, pp.100, 2010 (SCI-Expanded)
- LI. **Sarkoidoz Colybak Hastaligi Ve Derin Ven Trombozu Nadir Bir Birliktelik**
ÇELİK G., ÇİLEDAĞ A., KESKİN O., ENSARİ A., Karabörk A., KAYA A.
Trakya Universitesi Tip Fakultesi Dergisi, vol.28, pp.450-452, 2010 (SCI-Expanded)
- LII. **The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis.**
Dizdar E. A., Sekerel B. E., Keskin O., Kalaycı O., Adaloglu G., Dogan C., Tuncer A.
International journal of pediatric otorhinolaryngology, vol.71, pp.843-9, 2007 (SCI-Expanded)

Articles Published in Other Journals

- I. **A case report of reversible intracranial lesions after long-term Azathioprine therapy in an autoimmune hepatitis patient**
Hasan A. A., Bulut E., KESKİN O.
Hepatology Forum, vol.4, no.2, pp.78-81, 2023 (Scopus)
- II. **A rare benign tumor of the liver mimicking angiosarcoma: Anastomosing hemangioma**
Ismayilov R., BABAĞLU B., KESKİN O.
Northern Clinics of Istanbul, vol.10, no.4, pp.524-526, 2023 (ESCI)
- III. **Behçet's Disease-related Budd–Chiari Syndrome Successfully Managed with anti-TNF Antibody: A Case Report and Review of the Literature**
ERUL E., Uzun G. S., KÖKSAL D., KESKİN O., UYSAL S., İNKAYA A. Ç., KALYONCU U.
European Journal of Case Reports in Internal Medicine, vol.9, no.8, 2022 (Scopus)
- IV. **Drug-Associated Thrombocytopenia as a Rare and Devastating Side Effect of Octreotide in a Cirrhotic Patients: A Case Report and Current Literature Review**
ALTINTOP S. E., GÜVEN A. T., KESKİN O.
HASEKİ TIP BULTENİ-MEDICAL BULLETIN OF HASEKİ, vol.59, no.3, pp.265-267, 2021 (ESCI)
- V. **Systemic Radiopharmaceutical Agents Sm 153 may be Dangerous in Hepatocellular Carcinoma**
KESKİN O., SOYDAL Ç., DEDA X., MANTI B., TÜZÜN A. E.
World Journal of Nuclear Medicine, vol.14, pp.51, 2015 (ESCI)
- VI. **The Risk of Ileocolonic Perforation in Patients with Behçet s Disease Report of Three Cases and Review of the Literature**
BEKTAŞ M., KALKAN Ç., SOYKAN A. İ., BOYVAT A., SAVAŞ B., GEÇİM İ. E., KESKİN O., KIRCALI E., TÜZÜN A. E., ÖRMECİ N.
Journal of Gastrointestinal & Digestive System, vol.4, 2014 (Peer-Reviewed Journal)
- VII. **An Interesting Case of Early Multifocal Gastric Cancer**
KESKİN O., ÖRMECİ N.
Euroasian Journal of Hepato-Gastroenterology, vol.2, pp.116-118, 2012 (Peer-Reviewed Journal)
- VIII. **Effects of Helicobacter pylori infection and long term protonpump inhibitor use on enterochromaffin like cells**
BEKTAŞ M., SARAÇ F. N., ÇETİNKAYA H., TÖRÜNER M., ERDEMLİ E., KESKİN O., SOYKAN A. İ., OKTAY E. İ., KORKUT E., ÜSTÜN Y., et al.
Annals of Gastroenterology, vol.25, pp.123-127, 2012 (Scopus)
- IX. **Double Pylorus An Uncommon Endoscopic Finding**
KESKİN O., SOYKAN A. İ.
Journal of Medical Cases, vol.3, pp.172-173, 2012 (Peer-Reviewed Journal)
- X. **Use of endoscopic band ligation for treatment of postpolypectomy hemorrhage**
BEKTAŞ M., KESKİN O., KORKUT E., Üstün Y., Gupta V., Aniktar H., ÇETİNKAYA H., Bahar K., SOYKAN A. İ.
Endoskopi, vol.19, pp.104-105, 2011 (Peer-Reviewed Journal)
- XI. **Treatment of Mallory Weiss syndrome using argon plasma coagulation**
BEKTAŞ M., KORKUT E., İDİLMAN R., KESKİN O., Üstün Y., Gupta V., Bahar K.
Endoskopi, vol.19, pp.68-70, 2011 (Peer-Reviewed Journal)
- XII. **Toksik Megakolon ile İlgili Literatürün Gözden Geçirilmesi ve İlginç Bir Olgu Sunumu**
KESKİN O., ERDEN G. A., Özden A.
Güncel Gastroenteroloji, vol.11, pp.76-84, 2007 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **İndetermine kolit, mikroskopik kolit**
TÖRÜNER M., KESKİN O.

Refereed Congress / Symposium Publications in Proceedings

- I. **Investigation of the relationship between respiratory muscle strength and endurance capacity in liver cirrhosis: a pilot study**
TAŞKIN B., VARDAR YAĞLI N., SAĞLAM M., KESKİN O., DOĞRUL A. B.
Annual congress of the European-Respiratory-Society (ERS), Milan, Italy, 9 - 13 September 2023
- II. **Comparison of Respiratory Muscle Strength, Functional Capacity and Peak Oxygen Uptake In Patients With End-Stage Liver Disease and Liver Transplantation**
TAŞKIN B., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KESKİN O., DOĞRUL A. B.
European Respiratory Society Virtual Congress, 7 - 09 September 2020, vol.56, pp.2970
- III. **THE EFFECT OF PRETRANSPLANT INFECTIONS TO CLINICAL OUTCOME IN LIVE DONOR LIVER TRANSPLANT RECIPIENTS**
ÇINAR G., AKDEMİR KALKAN İ., AZAP A., BALCI D., KIRIMKER E. O., KESKİN O., YURTAYDIN S. C., ÖRMECİ N.
1st INTERNATIONAL TRANSPLANT NETWORK CONGRESS, 17 - 21 October 2018
- IV. **Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE-B Cohort**
Papatheodoridis G. V., Dalekos G. N., YURTAYDIN S. C., Sypsa V., van Bömmel F., Buti M., Calleja J. L., Chi H., Goulis I., Manolakopoulos S., et al.
AASLD 2018, 9 - 13 November 2018
- V. **Renal Problems in Patients with Solid Organ Transplanted**
KESKİN O.
APASL 2018 SINGLE TOPIC CONFERENCE, 27 - 29 September 2018
- VI. **İNFLAMATUVAR BARSAK HASTALIĞI'NDASITOMEGALOVİRÜS (CMV) ENFEKSİYONU SIKLIĞIRISK FAKTÖRLERİ VE KLİNİK SEYİR**
MANTI B., TÖRÜNER M., KESKİN O.
34. Ulusal Gastroenteroloji Haftası, Turkey, 1 - 06 December 2017
- VII. **Cytomegalovirus infection in inflammatory bowel diseases in a large single center cohort**
TÖRÜNER M., MANTI B., KESKİN O.
Advances in İnflammatory Bowel Diseases (AIBD) 2017, 9 - 11 November 2017
- VIII. **Living Donor Liver Transplantation using ALPPS procedure: case report**
BALCI D., KIRIMKER E. O., KESKİN O., ÜSTÜNER E., YILMAZ A. A., KARADAĞ ERKOÇ S., BAYTAŞ V., YURTAYDIN S. C., ÖRMECİ N., DÖKMECİ A., et al.
18th Congress of the European Society for Organ Transplantation, Barcelona, Spain, 24 - 27 September 2017
- IX. **Living Donor Liver Transplantation Using ALPPS Procedure: Case Report.**
BALCI D., KIRIMKER E. O., KESKİN O., ÜSTÜNER E., YILMAZ A. A., KARADAĞ ERKOÇ S., BAYTAŞ V., YURTAYDIN S. C., ÖRMECİ N., DÖKMECİ A., et al.
18th Congress of the European Society for Organ Transplantation, 24 - 27 September 2017
- X. **A step-up approach for complex biliary anatomy using microsurgical biliary reconstruction in living donor liver transplantation**
BALCI D., KIRIMKER E. O., KOLOĞLU M., YILMAZ A. A., KARADAĞ ERKOÇ S., ADAKLI B., ERDEN G. A., ÜSTÜNER E., DUMAN B., AZAP A., et al.
International Congress of ILTS, ELITALIcage, 24 - 27 May 2017
- XI. **Value of non-invasive fibrosis markers in chronic hepatitis D**
KALKAN Ç., KARAKAYA M. F., KESKİN O., ÇALIŞKAN KARTAL A., KARATAYLI E., BOZDAYI A. M., İDİLMAN R., YURDCU E., YURTAYDIN S. C.
INTERNATIONAL LIVER CONGRESS 2017, 19 - 23 April 2017, vol.66

- XII. **In patients under treatment, chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B**
KESKİN O., İDİLMAN R., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., YURTAYDIN S. C.
INTERNATIONAL LIVER CONGRESS 2017, 19 - 23 April 2017
- XIII. **The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis**
YURTAYDIN S. C., İDİLMAN R., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., KESKİN O., Yurdcu E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., Koh C., et al.
International Liver Congress, 19 - 23 April 2017, vol.66
- XIV. **A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study**
YURTAYDIN S. C., İDİLMAN R., KESKİN O., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., Yurdcu E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., Koh C., et al.
International Liver Congress 2017, 19 - 23 April 2017, vol.66
- XV. **Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy**
Lutterkort G. L., Wranke A., Hengst J., YURTAYDIN S. C., Weber K., Hardtke S., KESKİN O., Manns M.
International Liver Congress 2017, 19 - 23 April 2017, vol.66
- XVI. **Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis Interim Results From The Lowr Hdv 2 Study**
YURTAYDIN S. C., İDİLMAN R., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., KESKİN O., KARATAYLI E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., Koh C., et al.
AASLD 2016, 11 November 2016
- XVII. **Hepatoselüler kanser gelişiminde kronik hepatit D Hepatit B ye göre daha büyük risk faktörüdür**
KESKİN O., KARAKAYA M. F., KALKAN Ç., ÇALIŞKAN KARTAL A., İDİLMAN R., YURTAYDIN S. C.
Ulusal Gastroenteroloji Haftası 2016, Turkey, 21 November 2016
- XVIII. **Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B**
KESKİN O., KARAKAYA M. F., KALKAN Ç., ÇALIŞKAN KARTAL A., İDİLMAN R., YURTAYDIN S. C.
AASLD 2016, 11 November 2016
- XIX. **Viral Dominance patterns are associated with distinct systemic inflammatory patterns in patients with hepatitis delta**
Lutterkort G. L., YURTAYDIN S. C., Wranke A., Hardtke S., KESKİN O., Manns M. P., Wedemeyer H., Heidrich B.
AASLD 2016, 11 - 15 November 2016
- XX. **The risk of hepatocellular carcinoma HCC is decreasing after the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients**
Papatheodoridis, G. V., YURTAYDIN S. C., Dalekos G. N., Buti M., Chi H., van Bömmel F., Calleja J. L., Sypsa V., Goulis I., Manolakopoulos S., et al.
AASLD 2016, 11 November 2016
- XXI. **The Prenylation Inhibitor Lonafarnib Can Induce Post Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis**
YURTAYDIN S. C., İDİLMAN R., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., KESKİN O., KARATAYLI E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., Koh C., et al.
AASLD 2016, 11 November 2016
- XXII. **The Role Of Genetic Variability Of PNPLA3 rs738409 On Predisposition To Non Alcoholic Fatty Liver Disease In Lean Patients**
İDİLMAN R., ÖZEN KARATAYLI S. C., KARAKAYA M. F., KESKİN O., GÖZÜKARA B., SAVAŞ B., BOZDAYI A. M., ELHAN A. H., YURTAYDIN S. C.
AASLD 2016, 11 November 2016
- XXIII. **Hepatocellular carcinoma HCC is the only factor affecting the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or**

tenofovir TDF therapy

Papatheodoridis G. V., Dalekos G. N., YURTAYDIN S. C., van Bömmel F., Buti M., Sypsa V., Goulis J., Chi H., Manolakopoulos S., Loglio A., et al.

American Association of Study of Liver disease (AASLD) 2016, 11 - 15 November 2016

- XXIV. **Kronik delta hepatit tedavisinde uzun süreli interferon tedavisi süreğen virolojik yanıtı artırmakta ve doğal süreci iyileştirmektedir**
KESKİN O., TÜZÜN A. E., KABAÇAM G., KARAKAYA M. F., ÇALIŞKAN KARTAL A., KARATAYLI E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., İDİLMAN R., YURTAYDIN S. C.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- XXV. **Düşük viral yüklü HBV taşıyıcılarının prospektif analizi ve gerçek inaktif taşıyıcıların ayırımında ve takibinde kantitatif HbsAg ölçümünün yeri**
KESKİN O., YAKUT M., KARAKAYA M. F., SEVEN G., KARATAYLI E., ÖZEN KARATAYLI S. C., TÜZÜN A. E., ÇALIŞKAN KARTAL A., BOZDAYI A. M., İDİLMAN R., et al.
32. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 29 November 2015
- XXVI. **Prolongation of interferon therapy increases maintained virological response rates and improves the natural course of chronic delta hepatitis**
KESKİN O., TÜZÜN A. E., KARAKAYA M. F., KALKAN Ç., ÇALIŞKAN KARTAL A., KARATAYLI E., ÖZEN KARATAYLI S. C., BOZDAYI A. M., İDİLMAN R., YURTAYDIN S. C.
AASLD 2015, 13 - 17 November 2015
- XXVII. **Etiology and Natural Course of End Stage Liver Disease in the Real World Setting**
DEDA X., KALKAN Ç., KESKİN O., TÜZÜN A. E., YAKUT M., KILIÇ G., KARAKAYA M. F., İDİLMAN R.
Digestive Disease Week 2015, 16 - 19 May 2015, vol.148, pp.499
- XXVIII. **EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONIC HEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC**
Papatheodoridis G. V., Dalekos G. N., YURTAYDIN S. C., Buti M., Sypsa V., Goulis I., Calleja J., Chi H., Manolakopoulos S., Mangia G., et al.
EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS, 22 - 26 April 2015
- XXIX. **Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis**
YURTAYDIN S. C., İDİLMAN R., Choong I., KALKAN Ç., KESKİN O., KARAKAYA M. F., TÜZÜN A. E., KARATAYLI E., BOZDAYI A. M., Cory D., et al.
EASL 2015 Annual Meeting of International Liver Congress, 22 - 26 April 2015
- XXX. **On treatment HBsAg kinetics to predict long term HDV RNA response to peg IFNa treatment of hepatitis delta**
WÖBSE M., Hardtke S., Stefanie E., Heidrich B., Bremer B., KESKİN O., Koch A., Manns M., Wedemeyer H., YURTAYDIN S. C.
EASL 2015 50th Annual Meeting of International Liver Congress, 22 - 26 April 2015
- XXXI. **UNDERSTANDING HEPATITIS DELTA VIRUS AND HBsAg KINETICS DURING TREATMENT WITH PRENYLATION INHIBITOR LONAFARNIB VIA MATHEMATICAL MODELING**
Canini L., Koh C., Kotler S., Zhao X., Uprichard S. L., Haynes Williams V., Winters M. A., Subramanya G., Cooper S. L., Pinto P., et al.
EASL 2015 ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS, 22 - 26 April 2015
- XXXII. **The role of genetic variability of pnp1a3 rs738409 on histological progression of non alcoholic fatty liver disease**
İDİLMAN R., KESKİN O., ÖZEN KARATAYLI S. C., KABAÇAM G., TÜZÜN A. E., SAVAŞ B., ELHAN A. H., BOZDAYI A. M.
24th Annual Conference of APASL, 2015 İSTANBUL, 12 - 15 March 2015
- XXXIII. **Otoimmün hepatit tedavisi sonucu oluşan non travmatik avasküler nekroz**
Koç U., KESKİN O., ÖZKAN H.
31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014
- XXXIV. **Kronik delta hepatitte pegile interferon tedavisinde sonlanım prediktörü olarak serum HDV RNA**

KESKİN O., KALKAN Ç., DEDA X., TÜZÜN A. E., KARAKAYA M. F., ZEUZEM S., MANNS M., DALEKOS G., YALÇIN K., BOZKAYA H., et al.

31. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 25 - 30 November 2014

XXXV. **Budesonid tedavisine iyi yanıt veren atipik prezentasyonlu ileri yaş otoimmün pankreatit vakası**

KESKİN O., BİR K., TÜZÜN A. E., BEKTAŞ M., ÇINAR K., BOZKAYA H.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XXXVI. **Nükleozit id analog tedavisi ve düşük doz hepatit b immunoglobulin kombinasyonunun posttransplant HBV rekürrensi üzerine uzun dönem etkinliği**

İDİLMAN R., AKYILDIZ M., KESKİN O., TÜZÜN A. E., GÜLER N., GÜNGÖR G., ERDOĞAN Y., DAYANGAÇ M., BALCI D., HAZİNEDAROĞLU S. M., et al.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XXXVII. **Hepatit B enfeksiyonuna bağlı sirotik hastalarda uzun süreli oral antiviral ajan kullanımının hastalık seyrine etkisi**

KILIÇ G., KESKİN O., TÜZÜN A. E., KALKAN Ç., DEDA X., KARAKAYA M. F., İDİLMAN R.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XXXVIII. **Sistemik radyofarmasötik ajanların kullanımı Sm 153 hepatoselüler kanser hastalarında tehlikeli olabilir vaka raporu**

KESKİN O., MANTI B., SOYDAL Ç., DEDA X., TÜZÜN A. E.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XXXIX. **Yaygın lenfadenopatileri gelişen ilginç bir primer sklerozan kolanjit olgusu**

KESKİN O., AVANOĞLU A., KARAKAYA M. F., TÜZÜN A. E., ÇINAR K., İDİLMAN R.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XL. **Hepatoselüler kanser hastasında oral trombopoietin analogu deneyimi vaka sunumu**

KESKİN O., AKAY B., TÜZÜN A. E., ÇINAR K., BOZKAYA H.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XLI. **Otoimmün gastrit zemininde tip 1 gastrik karsinoid tümör gelişen ve gelişmeyen hastaların özelliklerinin karşılaştırılması**

KESKİN O., TÜZÜN A. E., KARAKAYA M. F., ÇETİNKAYA H., BEKTAŞ M., SOYKAN A. İ.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XLII. **Uzun süreli tenofovir disoproksil fumarat tedavisi radyolojik siroz bulgularını geriletir**

KESKİN O., UZUN Ç., ERDEN G. A., İDİLMAN R.

31. Ulusal Gastroenteroloji Haftası, Turkey, 25 - 30 November 2014

XLIII. **CLINICAL SIGNIFICANCE OF MEAN PLATELET VOLUME PLATELET CRIT PLATELET LYMPHOCYTERATIO AND NEUTROPHIL LYMPHOCYTERATIO IN THE DIFFERENTIATION OF PATIENTS WITH GASTRIC PRECANCEROUS LESIONS**

KALKAN Ç., ATEŞ C., KESKİN O., YAKUT M., KARAKAYA M. F., DEDA X., SOYKAN A. İ.

22nd United European Gastroenterology Week, Viyana, Austria, 18 - 22 October 2014

XLIV. **Early on treatment HDV RNA kinetics are not predictive for long term response to a PEG IFN α therapy of hepatitis delta**

Wöbse M., YURTAJDIN S. C., Ernst S., Hardtke S., Heidrich B., Bremer B., KESKİN O., İDİLMAN R., Koch A., Manns M. P., et al.

AASLD 2014 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7 - 11 November 2014

XLV. **The long term efficacy of combination of nucleoside analogue treatment and low dose hepatitis b immunoglobulin on posttransplant HBV recurrence**

İDİLMAN R., AKYILDIZ M., KESKİN O., TÜZÜN A. E., YILMAZ T. U., GÜLER N., YAPRAK O., GÜNGÖR G., ERDOĞAN Y., DAYANGAÇ M., et al.

AASLD 2014 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7 - 11 November 2014

XLVI. **Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans**

Koh C., YURTAJDIN S. C., Cooper S., Cory D., Dahari H., Williams V. H., Winters M. A., Bys M., Choong I. C., İDİLMAN

R., et al.

AASLD 2014 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7 - 11 November 2014

- XLVII. Timing of hepatocellular carcinoma HCC development and predictability of a modified PAGE B risk score in caucasian chronic hepatitis B CHB patients treated with entecavir ETV or tenofovir TDF**
Papatheodoridis G. V., Dalekos G. N., Sypsa V., YURTAYDIN S. C., Buti M., Goulis I., Chi H., Manolakopoulos S., Mangia G., Gatselis N., et al.
AASLD 2015, 13 - 17 November 2014
- XLVIII. Hepatoselüler kanser hastalarında perkütan etanol enjeksiyonu PEI ve radyofrekans ablasyon RFA tedavilerinin değerlendirilmesi Tek merkez deneyimi**
DÖKMECİ A., KESKİN O., TÜZÜN A. E., KABAÇAM G., ÖRMECİ N., ÖZKAN H., KARAYALÇIN S., BAHAR K.
11. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 24 - 28 September 2014
- XLIX. PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED INTERFERON a 2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT THE HIDIT 2 STUDY**
Wedemeyer H., YURTAYDIN S. C., Ernst S., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., et al.
EASL 49 th Annual Meeting of International Liver Congress, 9 - 13 April 2014
- L. PAGE B RISK SCORE FOR HEPATOCELLULAR CARCINOMA HCC DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B CHB PATIENTS RECEIVING ENTECAVIR ETV OR TENOFOVIR TDF**
Papatheodoridis G., Dalekos G., Sypsa V., YURTAYDIN S. C., Buti M., Goulis J., Arends P., Manolakopoulos S., Mangia G., Gatselis N., et al.
EASL 49th Annual Meeting of the International Liver Meeting, 9 - 13 April 2014
- LI. ENTECAVIR AND TENOFOVIR MONOTHERAPY IN TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS B A MULTICENTER TURKISH STUDY IN CLINICAL PRACTICE**
İDİLMAN R., KESKİN O., GÜNŞAR F., KORUK M., MERAL C., TÜZÜN A. E., GÜLŞEN M. T., ELHAN A. H., AKARCA U. S., YURTAYDIN S. C.
EASL 49th Annual Meeting of the International Liver Congress, 9 - 13 April 2014
- LII. THE ASSOCIATION BETWEEN GASTROESOPHAGEAL FLAP VALVE FUNCTION AND GASTROESOPHAGEAL REFLUX SYMPTOMS ENDOSCOPIC FEATURES HELICOBACTER PYLORI STATUS AND BODY MASS INDEX**
KESKİN O., TÜZÜN A. E., YAMAN A., ÇETİNKAYA H., SOYKAN A. İ.
21st United European Gastroenterology Week, 12 - 16 October 2013
- LIII. 96 weeks of pegylated Interferon alpha 2a plus tenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study**
Wedemeyer H., YURTAYDIN S. C., Ernst S., Caruntu F., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., et al.
AASLD 2013, 1 - 05 November 2013
- LIV. Inactive hepatitis B carriers are prone to HBsAg loss rather than reactivation a 5 year prospective follow up study**
KESKİN O., YAKUT M., KALKAN Ç., ÖZEN KARATAYLI S. C., KARATAYLI E., İDİLMAN R., BOZDAYI A. M., YURTAYDIN S. C.
AASLD 2013 The 64th Annual Meeting, The American Association For The Study Of Liver Diseases, 1 - 05 November 2013
- LV. Effectiveness and safety of entecavir and tenofovir in chronic hepatitis b patients A multicenter Turkish study in clinical practice**
İDİLMAN R., GÜNŞAR F., KESKİN O., Meral C., KORUK M., GÜLŞEN M. T., ELHAN A. H., BOZDAYI A. M., AKARCA U. S., YURTAYDIN S. C.
AASLD 2013, 1 - 05 November 2013
- LVI. Risk and risk factors of hepatocellular carcinoma HCC in Caucasian chronic hepatitis B CHB patients with or without cirrhosis treated with entecavir ETV or tenofovir TDF**
Papatheodoridis G. V., Dalekos G. N., YURTAYDIN S. C., Goulis I., Arends P., Buti M., Sypsa V., Manolakopoulos S.,

Mangia G., Gatselis N., et al.

AASLD 2013, 1 - 05 November 2013

- LVII. Gastroözofageal bölgenin endoskopik görünümünün reflü semptomları özofajit ve hiatal herni ile ilişkisi**
KESKİN O., TÜZÜN A. E., KALKAN Ç., ÇETİNKAYA H., SOYKAN A. İ.
10. Hepato Gastroenteroloji Kongresi, Turkey, 25 - 28 September 2013
- LVIII. Primer biliyer siroz hastasında gelişen akut başlangıçlı ağır otoimmün hepatit olgusu ve yaklaşım**
KESKİN O., USLU A., DOST F. S., İDİLMAN R.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 September 2013
- LIX. Minimal Hepatik Ensefalopati MHE Tanısı için Kullanılacak Psikometrik Hepatik Ensefalopati Skorlama PHES Testinin Türk İnsanımda Validasyonu**
ÖZBAŞ B., ORUÇ N., KARAHAN İ., KESKİN O., İDİLMAN R., GÜNŞAR F., ÖZÜTEMİZ A. Ö., YURTAYDIN S. C.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 September 2013
- LX. Kronik hepatit b hastalarında entekavir ve tenofovir etkinlik ve güvenilirliği Çok merkezli çalışma**
İDİLMAN R., GÜNŞAR F., KESKİN O., GÜLŞEN M. T., MERAL C., BOZDAYI A. M., ELHAN A. H., KORUK M., AKARCA U. S., YURTAYDIN S. C.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 September 2013
- LXI. Pankreas kistlerinin klinik laboratuvar radyolojik ve endosonografik bulguları**
BEKTAŞ M., ÖZTÜRK B., DÖKMECİ A., ŞEN S., KESKİN O., TÜZÜN A. E., KALKAN Ç., CEYHAN K., ÇINAR K., TÖRÜNER M., et al.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 September 2013
- LXII. Pankreas solid ve kistik kitlelerin tanısında EUS ve BT nin rollerinin karşılaştırmalı değerlendirilmesi**
BEKTAŞ M., ÖZTÜRK B., ÜSTÜN Y., KARAYALÇIN S., DÖKMECİ A., KESKİN O., TÜZÜN A. E., KALKAN Ç., CEYHAN K., ÇINAR K., et al.
30. Ulusal Gastroenteroloji Haftası, Turkey, 11 - 15 September 2013
- LXIII. Kronik hepatit D tedavisinde nükleozid analog monoterapisi**
KESKİN O., İDİLMAN R., KABAÇAM G., YAKUT M., ÖNDER F. O., MANNS M., WEDEMEYER H., YURTAYDIN S. C.
29. Ulusal Gastroenteroloji Haftası, Turkey, 20 - 25 November 2012
- LXIV. Tedavisi zor bir ülseratif kolit hastası**
KESKİN O., BEKTAŞ M., TÜZÜN A. E., TÖRÜNER M.
29. Ulusal Gastroenteroloji Haftası, Turkey, 20 - 25 November 2012
- LXV. Non alkolik yağlı karaciğer hastalığında metformin tedavisinin kardiyovasküler risk üzerine etkisi**
KESKİN O., KABAÇAM G., TÜZÜN A. E., ATEŞ C., TURHAN S., ÇORAPÇIOĞLU D., İDİLMAN R.
29. Ulusal Gastroenteroloji Haftası, Turkey, 20 - 25 November 2012
- LXVI. Endoskopik Ultrasonoğrafi Bulguları Submukozal Lezyonların Malign Olma Olasılığında Belirleyici Olabilir mi**
KESKİN O., BEKTAŞ M., AGAYEVA S., ÖZTÜRK B., TÜZÜN A. E., ÇINAR K.
29. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 20 - 25 November 2012
- LXVII. Kronik Hepatit B ye bağlı siroz hastalarında tenofovir tedavisinin uzun süreli sonuçları Etkinlik ve güvenilirlik**
KESKİN O., İDİLMAN R., TÜZÜN A. E., TÖRÜNER M., BOZDAYI A. M., ÇINAR K., YURTAYDIN S. C.
29. Ulusal Gastroenteroloji Haftası, Turkey, 20 - 25 November 2012
- LXVIII. Non Alkolik yağlı karaciğer hastalığında PNPLA3 GG genotipikaraciğer fibrozisi ile ilişkilidir**
KESKİN O., İDİLMAN R., ÖZEN KARATAYLI S. C., ANIKTAR H., KABAÇAM G., SAVAŞ B., BOZDAYI A. M., ÇINAR K.
29. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 20 - 25 November 2012
- LXIX. Pegylated Interferon a 2a plus Tenofovir or Placebo for the treatment of hepatitis delta First results of the HIDIT 2 study**
YURTAYDIN S. C., Wedemeyer H., Caruntu F. A., Curescu M. G., YALÇIN K., AKARCA U. S., GÜREL S., Zeuzem S., Erhardt A., Lüth S., et al.
AASLD 2012 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9 - 13 November 2012

- LXX. **The impact of sequential proton density fat fraction calculation by MRI for quantification of hepatic steatosis in nonalcoholic fatty liver disease a longitudinal follow up study**
İDİLMAN İ. S., KESKİN O., KABAÇAM G., SAVAŞ B., KARÇALTINCABA M., ÇINAR K., İDİLMAN R.
AASLD 2012 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9 - 13 November 2012
- LXXI. **Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on treatment parameters**
ÖNDER F. O., Erhardt A., İDİLMAN R., KESKİN O., Dalekos G. N., YALÇIN K., Manns M. P., Wedemeyer H., YURTAYDIN S. C.
AASLD 2012 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9 - 13 November 2012
- LXXII. **Characterization of the inactive HBsAG carrier state with 4 years of follow up**
YAKUT M., KESKİN O., SEVEN G., KABAÇAM G., KARATAYLI E., ÖZEN KARATAYLI S. C., BEKTAŞ M., BOZDAYI A. M., İDİLMAN R., YURTAYDIN S. C.
AASLD 2012 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9 - 13 November 2012
- LXXIII. **Response to tenofovir treatment of treatment naive and adefovir experienced patients with chronic hepatitis b**
KESKİN O., Örmeci A. C., Kabaçam G., AKYÜZ F., Anıktar H., KARACA Ç., İDİLMAN R., KAYMAKOĞLU S., YURTAYDIN S. C.
AASLD 2012 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9 - 13 November 2012
- LXXIV. **Portal hipertansiyona bağlı gelişen semptomatik hipersplenizmin düşük doz dalak radyoterapi ile tedavisi**
BEKTAŞ M., KESKİN O., BAHAR K., SOYKAN A. İ., İDİLMAN R., ÇELİK M., SANLIDİLEK U. N., ÇINAR K.
9. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 26 - 30 September 2012
- LXXV. **Tip 1 gastrik karsinoid tümörlerin klinik laboratuvar ve endoskopik özellikleri ve uygulanan tedavi yöntemleri**
BEKTAŞ M., SOYKAN A. İ., KESKİN O., İLGEN U., ÇETİNKAYA H., TÜZÜN A. E., ENSARİ A., SAVAŞ B., ÇAKMAK A., ÇINAR K.
9. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 26 - 30 September 2012
- LXXVI. **Tip 1 gastrik karsinoid tümörlerin tedavisinde uzun salınlı somatostatin etkisi**
BEKTAŞ M., KESKİN O., İLGEN U., ÇETİNKAYA H., TÜZÜN A. E., ENSARİ A., SAVAŞ B., SOYKAN A. İ.
9. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 26 - 30 September 2012
- LXXVII. **Özefagus kanserlerinin evrelendirmesinde endoskopik ultrasonografinin yeri**
BEKTAŞ M., YÜKSEL C., ENÖN S., KESKİN O., TÜZÜN A. E., KUTLAY H., ÖKTEN İ., ÇINAR K.
9. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 26 - 30 September 2012
- LXXVIII. **Anti HCV pozitifliği otoimmün gastrit hastalarında hepatit C infeksiyonu ile ilişkili olmayabilir**
SOYKAN A. İ., MUSTAFA Y., KESKİN O.
9. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 26 - 30 September 2012
- LXXIX. **Interleukin 23 Receptor and ATG16L1 Gene Polymorphisms in Inflammatory Bowel Diseases and the Association With the Clinical Course**
KABAÇAM G., ÖZEN KARATAYLI S. C., KESKİN O., BEKTAŞ M., ÇETİNKAYA H., PALABIYIKOĞLU M., SOYKAN A. İ., BOZDAYI A. M., TÖRÜNER M.
Digestive Disease Week 2012, 19 - 22 May 2012
- LXXX. **RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT NAIVE VS ADEFOVIR RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B**
KESKİN O., ÖRMECİ A., KABAÇAM G., AKYÜZ F., ANIKTAR H., KARACA Ç., İDİLMAN R., KAYMAKOĞLU S., YURTAYDIN S. C.
EASL 47th Annual Meeting of the International Liver Congress 2012, 18 - 22 April 2012
- LXXXI. **Adefovir rezistan ve nükleozid naiv hastalarda tenofovir tedavisine yanıt 24 aylık takip sonuçları**

KESKİN O., ÇİFÇİBAŞI ÖRMECİ A., KABAÇAM G., AKYÜZ F., ANIKTAR H., KARACA Ç., İDİLMAN R., KAYMAKOĞLU S., YURTAYDIN S. C.

28. Ulusal Gastroenteroloji Haftası, Turkey, 16 - 20 November 2011

LXXXII. Hermansky Pudlak sendromu Crohn hastalığı birlikteliği

KESKİN O., BEKTAŞ M., UZUN D. Y., TÖRÜNER M.

28. Ulusal Gastroenteroloji Haftası, Turkey, 16 - 20 November 2011

LXXXIII. İltihabi barsak hastalıklarında interlökin 23 reseptör ve ATG16L1 gen polimorfizmleri ve klinikle ilişkisi

KABAÇAM G., ÖZEN KARATAYLI S. C., KESKİN O., ÇETİNKAYA H., PALABIYIKOĞLU M., SOYKAN A. İ., BOZDAYI A. M., TÖRÜNER M.

28. Ulusal Gastroenteroloji Haftası, Turkey, 16 - 20 November 2011

LXXXIV. Endosonografi sırasında saptanan subepitelyal lezyonların özellikleri ve bu lezyonlarda çap ve diğer morfolojik malignite kriterleri arasındaki ilişki

BEKTAŞ M., KESKİN O., AGAYEVA S., ANIKTAR H., TÜZÜN A. E., ÖZTÜRK B., İDİLMAN R., ÇINAR K., BOZKAYA H., ÇETİNKAYA H., et al.

8. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 28 September - 02 October 2011

LXXXV. Skleroderma hastalarının özofagus motor fonksiyonları

BEKTAŞ M., KESKİN O., ŞAHİN DALGIÇ G., ANIKTAR H., TÜZÜN A. E., KUMRU G., ÖZTÜRK B., ÇETİNKAYA H., TÖRÜNER M., BEYLER A. R., et al.

8. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 28 September - 02 October 2011

LXXXVI. Barrett s zemininde özofagus kanser olguları

KESKİN O., BEKTAŞ M., YÜKSEL C., AGAYEVA S., ÖZTÜRK B., PAÇACI G., KUBİLAY P., ANIKTAR H., TÜZÜN A. E., ÖKTEN İ., et al.

8. Ulusal Hepato Gastroenteroloji Kongresi, Turkey, 28 September - 02 October 2011

LXXXVII. The prevalence and localization of diverticulosis coli in Turkish population

ÇETİNKAYA H., KESKİN O., BEKTAŞ M., TÜZÜN A. E., KABAÇAM G., SEVEN G., YAKUT M., ANIKTAR H., DOĞRU E., TÖRÜNER M., et al.

FALK SYMPOSIUM 178, 2 - 03 September 2011

LXXXVIII. Perikardiyal mezotelyomaya bağlı kardiyak tamponatın neden olduğu akut karaciğer yetmezliği

KESKİN O., BEKTAŞ M., TÜZÜN A. E., KUMRU G., GEREDİ D. M., KILIÇ G., PAÇACI G., ÖZTÜRK B., GERÇİK Ö., BEYLER A. R., et al.

8. Ulusal Hepatoloji Kongresi, Turkey, 1 - 05 June 2011

LXXXIX. Primer biliyer sirozlu hastalarda özofagus fonksiyonlarının manometrik değerlendirilmesi

BEKTAŞ M., SEVEN G., İDİLMAN R., YAKUT M., DOĞANAY ERDOĞAN B., KABAÇAM G., ÜSTÜN Y., KESKİN O., KORKUT E., ÇETİNKAYA H., et al.

8. Ulusal Hepatoloji Kongresi, Turkey, 1 - 05 June 2011

XC. Diş eti infiltrasyonu ile prezente olan AML M3 olgusu

KESKİN O., CERAN F., SİMTEN D., ÜRE Ü. B., TOKGÖZ G., SUNU C., FALAY M., ÖZET G.

36. Ulusal Hematoloji Kongresi, Turkey, 03 November 2010

Metrics

Publication: 155

Citation (WoS): 732

Citation (Scopus): 574

H-Index (WoS): 13

H-Index (Scopus): 12

Non Academic Experience

Bilecik Devlet Hastanesi

SAĞLIK BAKANLIĞI